The company launched a major cost-cutting program and made a significant acquisition, buying cancer specialist Seagen for US$43-billion, a move which Pfizer expects to boost revenue and profits.

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

Pfizer executives are still bullish on the opportunity for its own obesity and diabetes drugs under development, eyeing a potential opening for oral versions and an improved safet ...

Covid-19 vaccine victims sue Portuguese state; Victims “feel betrayed by those who should have protected them” ...

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) reported mixed Q3 results, with each company facing distinct market forces, ranging ...

Social Security is likely to deliver less income than you expect. But you can make up the difference and more via ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Pfizer has a well-diversified pipeline, with several late-stage assets to drive medium-term growth. Learn more about PFE ...

At Shionogi, a Japanese pharmaceutical company, executives pointed out that COVID is still flaring in Japan. In Japan, ...

Pfizer's pipeline features quite a few promising candidates that could be big winners in the future. CEO Albert Bourla highlighted some of them in the Q3 earnings call. Probably none is as eagerly ...

In parallel, the Court of Justice will hear details of a second case next month — the “Pfizergate” legal battle over access to alleged text messages between von der Leyen and Pfizer CEO Albert Bourla ...

In life, there’s a common expression that also carries over into the dividend investing world: If it seems too good to be true, it usually is ...